Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group

Abstract only

Saved in:

Bibliographic Details
Published in	Journal of clinical oncology Vol. 29; no. 15_suppl; p. 2029
Main Authors	Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Taillia, H., Frappaz, D., Schott, R., Honnorat, J., Fabbro, M., Tennevet, I., Ghiringhelli, F., Guillamo, J. S., Durando, X., Castera, D., Frenay, M., Campello, C., Guillevin, R., Skrzypski, J., Dabakuyo, T. S., Chinot, O. L.
Format	Journal Article
Language	English
Published	20.05.2011
Online Access	Get full text

Loading…